Sanus Advisory Asia
Sanus Asia is a Singapore based advisory firm providing investment and transaction-related services across Asia with a focus on Healthcare and Life Sciences.
We work with investors and high potential companies to assist growth/development across Asia through capital raising and strategic/operational support.
We seek to identify high potential US/European Medtech and Digital Health companies with near-term commercialisation potential in Asia.
Will also consider earlier stage investments as a principal Angel investor if there is a strong Asian angle to the technology/business model.
Seroba Kernel Life Sciences
Seroba Kernel is a venture capital firm based in Dublin, Ireland, with representatives in the United Kingdom. The firm has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.
Daniel O'Mahony
PartnerSofia Angel Fund
Sofia Angel Group is a group of angel investors based in Minneapolis, Minnesota. The group solely focuses on investing in women-led businesses where women are the founders, or women are on the senior management team. Sofia Angel Group does not have a specific timeframe to make an investment, however would make an allocation by the end of 2013 if a compelling opportunity is identified. The group typically invests around $100,000 per company, however has the ability to invest up to $3 million through co-investments from the group’s members.
Barbara Nelsen
Sound Affects
Mona Jhaveri
Executive DirectorSymbient Product Development
Rapid Development of Injection Molded Medical Devices
From Concept Through Transfer-to-Manufacturing
Symbient specializes in engineering research and development, prototyping and design-for-manufacturing of innovative medical devices that use injection molded components. Our highly experienced team consists of mechanical and biomedical engineers, industrial designers, machinists and molding technicians. They leverage our in-house rapid prototyping, and prototype tooling fabrication and injection molding to create proven, manufacturable designs with unmatched speed, efficiency and precision. These designs make up our deep portfolio of over 300 successful devices that have collectively generated hundreds of millions of dollars. They include FDA Class I, II and III devices, developed under our ISO 13485 certified quality management system.
Our Services Include:
- Concept Development
- Development Engineering
- Design-for-Manufacturing
- Industrial Design
- Project Rescue
- Design Control per IOS 13485
- Finite Element Analysis (FEA)
- Design Verification Testing
- Test Method Development
- Transfer to Manufacturing
Our In-House Capabilities and Expertise Include:
- Stereolithography (SLA) Prototyping
- CNC Machining / Fabrication
- Prototype Mold Fabrication
- Prototype Injection Molding of Devices for Testing, Trials and Studies
- Liquid Injection Molded (LIM) Silicone Prototype Molding
- Product Reliability Testing
- Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
- Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
- Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.
Our Portfolio Includes:
- Diagnostics / Molecular Diagnostics
- Sample collection / preparation
- Life Sciences / Microfluidics
- OTC Consumer products
- Respiratory
- Surgical devices and clinical tools
- Drug Delivery
Lisa Coyne
Business Development ManagerLuke Helm
Director of Business DevelopmentSyncona Partners
Syncona Partners, founded in 2012, is an evergreen investment firm based in London, UK. The firm is an independent subsidiary of the Wellcome Trust who invested the initial £200m capitalization. The firm is mandated to invest in companies with the potential to make major breakthroughs in healthcare. The investment size will usually range from £1M – £20M per company. The firm seeks to create sustainable, profitable businesses, to support them with capital over the long term, for the benefit of patients, and to hold an ownership position to create value for the Wellcome Trust. The firm is actively screening new investment opportunities.
Chris Hollowood
PartnerTech Coast Angels
Founded in 1997, Tech Coast Angels is the largest angel investor group in the United States. Its members provide funding and guidance to more early-stage high-growth companies in Southern California than any other investment group. TCA members invest in companies in a wide range of industries including life sciences, biotech and health IT. TCA has more than 325 members including its venture capital affiliates in five networks in Los Angeles Orange County San Diego Westlake/Santa Barbara and the Inland Empire. The organization will finance on an opportunistic basis as long as substantial disruptive market opportunities exists. The firm has historically invested in Biotech Therapeutics & Diagnostics, Biotechnology R&D Services, Biotechnology Other, Medical Technology companies with sub sectors of Anti-Infectives, Bioinformatics, CRO (Contract Research Organization), Diagnostic Instrumentation, Diagnostic Services, Drug Delivery, Food, Industrial Biotechnology, Small Molecules, Small Molecule Therapeutics, Wound Care and indications including Diseases of the Nervous System, Infectious and Parasitic Diseases, Neoplasms/Cancer/Oncology, Respiratory.
Websites:
www.greenwingsbiomedical.com
techcoastangels.com
Richard Koffler
MemberTexo Ventures
TEXO Ventures is a healthcare venture capital firm that was founded in 29 and is based in Austin Texas. The firm operates as a hybrid of angel and venture capital. The recent fund closed at $15.4 million in 212. The firm focuses on making equity investments in the Medical Technology and Healthcare IT spaces at near commercialization or early commercialization stage. The firm typically invests ranging from $3 million to $5 million into a company. The firm plans to make 2-3 investments over the next 6-9 month. TEXO Ventures is open to consider companies across the US. The firm primarily focuses on healthcare which includes Health IT Technology enabled Health Services Chronic Disease Management Managed Care and Benefit Design. Although medical devices and functional diagnostics are considered for investment purposes Texo Ventures must see a clear regulatory pathway and obvious synergies with healthcare reform within a company. The firm's current investment portfolio includes companies in the area of medical technology. Within this field they are in areas such as diagnostic and therapeutic radiation devices electro mechanical medical devices re-usable instruments biomaterials and non-active implantable.